AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022)
AN2 Therapeutics (ANTX) posted quarterly Other Operating Expenses of $1.0 million for Q3 2022, up 100.0% quarter-over-quarter from $500000.0 in Q4 2021.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Other Operating Expenses (2021 - 2022) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Other Operating Expenses for 2 consecutive years, with $1.0 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Other Operating Expenses changed N/A year-over-year to $1.0 million; the TTM figure through Jun 2023 stood at $1.0 million (up 100.0% YoY), while the FY2022 annual figure was $1.0 million, up 33.33% from the prior year.
- Other Operating Expenses improved to $1.0 million in Q3 2022 per ANTX's latest filing, from $500000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $1.0 million in Q3 2022 and bottomed at $250000.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 1.00 Mn |
| Dec 31, 2021 | 500,000.00 |
| Jun 30, 2021 | 250,000.00 |